Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADUSNASDAQ:CSTLNYSE:PACSNASDAQ:VCYT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADUSAddus HomeCare$115.12-0.4%$110.24$88.96▼$136.72$2.13B0.81169,426 shs285,580 shsCSTLCastle Biosciences$20.35+3.0%$18.08$15.45▼$35.84$570.23M1.03425,686 shs1.39 million shsPACSPACS Group$13.01+1.2%$10.53$8.28▼$43.92$1.96B0.21819,519 shs1.41 million shsVCYTVeracyte$27.38+2.1%$28.59$19.73▼$47.32$2.10B2.09916,516 shs3.60 million shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADUSAddus HomeCare-0.45%+1.17%+1.63%+18.31%-3.68%CSTLCastle Biosciences+3.04%+9.88%+25.39%+2.06%-3.51%PACSPACS Group+1.27%-1.84%+32.20%+19.21%-55.61%VCYTVeracyte+2.13%+3.75%+2.47%-9.10%+21.69%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADUSAddus HomeCare4.2225 of 5 stars2.62.00.05.02.12.51.9CSTLCastle Biosciences2.2444 of 5 stars3.53.00.00.01.42.50.0PACSPACS Group2.6646 of 5 stars3.41.00.00.01.90.01.9VCYTVeracyte3.5594 of 5 stars3.41.00.04.32.80.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADUSAddus HomeCare 3.25Buy$142.5723.85% UpsideCSTLCastle Biosciences 3.00Buy$37.0081.82% UpsidePACSPACS Group 2.86Moderate Buy$34.29163.61% UpsideVCYTVeracyte 2.70Moderate Buy$40.9049.38% UpsideCurrent Analyst Ratings BreakdownLatest CSTL, ADUS, VCYT, and PACS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/20/2025ADUSAddus HomeCareJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$150.006/10/2025ADUSAddus HomeCareMacquarieSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$133.005/21/2025CSTLCastle BiosciencesScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$44.00 ➝ $40.005/8/2025ADUSAddus HomeCareMacquarieSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$129.00 ➝ $133.005/8/2025VCYTVeracyteUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$49.00 ➝ $42.005/8/2025VCYTVeracyteNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$51.00 ➝ $41.005/6/2025CSTLCastle BiosciencesLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $35.005/6/2025CSTLCastle BiosciencesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$42.00 ➝ $37.004/22/2025ADUSAddus HomeCareJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$150.00 ➝ $150.004/10/2025ADUSAddus HomeCareJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$150.00 ➝ $150.004/9/2025VCYTVeracyteGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$45.00 ➝ $37.00(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADUSAddus HomeCare$1.15B1.83$5.47 per share21.04$53.52 per share2.15CSTLCastle Biosciences$332.07M1.77$1.03 per share19.79$16.28 per share1.25PACSPACS Group$3.11B0.64N/AN/AN/A∞VCYTVeracyte$445.76M4.81$1.07 per share25.51$15.17 per share1.80Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADUSAddus HomeCare$73.60M$4.4325.9921.481.616.52%9.23%6.96%8/4/2025 (Estimated)CSTLCastle Biosciences$18.25M-$0.19N/AN/AN/A-1.46%3.41%2.95%8/4/2025 (Estimated)PACSPACS Group$112.87MN/A0.007.31N/AN/AN/AN/AN/AVCYTVeracyte$24.14M$0.4166.7838.03N/A7.13%6.14%5.60%8/5/2025 (Estimated)Latest CSTL, ADUS, VCYT, and PACS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/5/2025Q1 2025ADUSAddus HomeCare$1.33$1.42+$0.09$1.16$341.66 million$337.71 million5/5/2025Q1 2025CSTLCastle Biosciences-$0.08-$0.20-$0.12-$0.90$80.40 million$87.99 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADUSAddus HomeCareN/AN/AN/AN/AN/ACSTLCastle BiosciencesN/AN/AN/AN/AN/APACSPACS GroupN/AN/AN/AN/AN/AVCYTVeracyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADUSAddus HomeCare0.201.741.74CSTLCastle Biosciences0.029.379.19PACSPACS GroupN/AN/AN/AVCYTVeracyteN/A5.104.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADUSAddus HomeCare95.35%CSTLCastle Biosciences92.60%PACSPACS GroupN/AVCYTVeracyteN/AInsider OwnershipCompanyInsider OwnershipADUSAddus HomeCare4.60%CSTLCastle Biosciences6.50%PACSPACS GroupN/AVCYTVeracyte1.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADUSAddus HomeCare49,70318.40 million17.55 millionOptionableCSTLCastle Biosciences54028.87 million27.00 millionOptionablePACSPACS Group32,433152.40 millionN/AOptionableVCYTVeracyte79078.32 million77.22 millionOptionableCSTL, ADUS, VCYT, and PACS HeadlinesRecent News About These CompaniesAMI Asset Management Corp Has $1.44 Million Stock Holdings in Veracyte, Inc. (NASDAQ:VCYT)June 26 at 7:02 AM | marketbeat.comVeracyte, Inc. (NASDAQ:VCYT) Receives $40.90 Consensus Target Price from AnalystsJune 26 at 2:23 AM | americanbankingnews.comVeracyte, Inc. (NASDAQ:VCYT) Receives Average Rating of "Moderate Buy" from AnalystsJune 23, 2025 | marketbeat.comVeracyte (NASDAQ:VCYT) shareholders have earned a 19% return over the last yearJune 20, 2025 | finance.yahoo.comGAMMA Investing LLC Purchases 18,840 Shares of Veracyte, Inc. (NASDAQ:VCYT)June 19, 2025 | marketbeat.comCathie Wood’s ARK buys BWX stock, sells Adaptive BiotechJune 18, 2025 | investing.comExchange Traded Concepts LLC Increases Stake in Veracyte, Inc. (NASDAQ:VCYT)June 17, 2025 | marketbeat.comVeracyte, Inc. (NASDAQ:VCYT) Shares Purchased by Assenagon Asset Management S.A.June 14, 2025 | marketbeat.comVeracyte (NASDAQ:VCYT) Stock Rating Upgraded by Wall Street ZenJune 14, 2025 | marketbeat.comVeracyte (NASDAQ:VCYT) Shares Down 4.8% - Should You Sell?June 12, 2025 | marketbeat.comVeracyte (VCYT) Fell Despite Reporting Revenue Growth and Improved ProfitabilityJune 9, 2025 | msn.comCathie Wood's Ark Invest Loads Up On Veracyte, Offloads 3D SystemsJune 7, 2025 | benzinga.comInsider Selling: John Leite Sells Shares of Veracyte Inc (VCYT)June 6, 2025 | gurufocus.comVeracyte (VCYT) Down 13.6% Since Last Earnings Report: Can It Rebound?June 6, 2025 | msn.comCathie Wood’s ARK sells Palantir and Roblox, buys Veracyte and GuardantJune 4, 2025 | investing.comVeracyte (VCYT) Shares Pulled Back Despite Beating ExpectationsJune 3, 2025 | msn.comVeracyte, Inc. (NASDAQ:VCYT) Shares Sold by AEGON ASSET MANAGEMENT UK PlcJune 3, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 30,059 Shares of Veracyte, Inc. (NASDAQ:VCYT)June 2, 2025 | marketbeat.comVeracyte (NASDAQ:VCYT) Lowered to Hold Rating by Wall Street ZenJune 1, 2025 | marketbeat.comQuent Capital LLC Has $337,000 Stake in Veracyte, Inc. (NASDAQ:VCYT)June 1, 2025 | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Purchases New Stake in Veracyte, Inc. (NASDAQ:VCYT)June 1, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCSTL, ADUS, VCYT, and PACS Company DescriptionsAddus HomeCare NASDAQ:ADUS$115.12 -0.52 (-0.45%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$115.12 -0.01 (0.00%) As of 06/27/2025 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. The company operates through three segments: Personal Care, Hospice, and Home Health. The Personal Care segment provides non-medical assistance with activities of daily living. This segment offers services that include assistance with bathing, grooming, oral care, feeding and dressing, medication reminders, meal planning and preparation, housekeeping, and transportation services. The Hospice segment provides palliative nursing care, social work, spiritual counseling, homemaker, and bereavement counseling services for people who are terminally ill, as well as related services for their families. The Home Health segment offers skilled nursing and physical, occupational, and speech therapy for the individuals who requires assistance during an illness or after hospitalization. The company's payor clients include federal, state, and local governmental agencies; managed care organizations; commercial insurers; and private individuals. Addus HomeCare Corporation was founded in 1979 and is headquartered in Frisco, Texas.Castle Biosciences NASDAQ:CSTL$20.35 +0.60 (+3.04%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$20.36 +0.01 (+0.07%) As of 06/27/2025 05:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.PACS Group NYSE:PACS$13.01 +0.16 (+1.21%) Closing price 06/27/2025 03:59 PM EasternExtended Trading$12.99 -0.02 (-0.12%) As of 06/27/2025 06:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PACS Group, Inc., through its subsidiaries, operates skilled nursing facilities and assisted living facilities in the United States. The company also provides senior care and independent facilities. It engages in the acquisition, ownership, and leasing of health care-related properties. The company was founded in 2013 and is based in Farmington, Utah.Veracyte NASDAQ:VCYT$27.38 +0.57 (+2.13%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$27.50 +0.12 (+0.42%) As of 06/27/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Addition by Subtraction: Intel’s New Strategy Energizes Investors NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside QuantumScape Soars 30%: What Drove the Next-Gen EV Stock's Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.